Neurocrine Biosciences has announced that FDA has granted breakthrough therapy designation for NBI-98854 (Vesicular Monoamine Transporter 2 inhibitor) drug in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. ...Saturday, 1 November 2014
NBI-98854 Drug Receives Breakthrough Designation for Tardive Dyskinesia
Neurocrine Biosciences has announced that FDA has granted breakthrough therapy designation for NBI-98854 (Vesicular Monoamine Transporter 2 inhibitor) drug in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment